engleski

Prediction of Alzheimer's disease in subjects with mild cognitive impairment using biological markers from CSF

With the advent of new drugs such as gamma-secretase inhibitors, early detection of elderly subjects with mild cognitive impairment (MCI) who are destined to develop AD is becoming increasingly important. For this purpose, the three most commonly used CSF biomarkers (total tau, amyloid-ß42 protein and phosphorylated tau protein) have been evaluated in numerous studies, including ours. Majority of these investigations confirmed that CSF markers have high sensitivity to differentiate early and incipient AD from normal aging, major depressive disorder, alcoholic dementia and Parkinson’ s disease, but relatively lower specificity against other primary causes of dementia syndrome, such as frontotemporal and Lewy body dementia. In most studies, low amyloid-ß42 and high total tau protein in cerebrospinal fluid were found in about 90% of the MCI cases that progressed to AD as compared with the 10% stable MCI cases. Similarly, higher concentrations of tau protein phosphorylated on threonine 231 were found in MCI cohort that progressed to AD compared to those with stable MCI. It is concluded that pathological levels of two or more CSF markes can reliably predict MCI conversion to AD and correctly identify the stable form of MCI.

Alzheimer's disease ; amyloid-beta ; cerebrospinal fluid ; dementia ; early diagnosis ; mild cognitive impairment ; tau protein

nije evidentirano